Abstract: This systematic review aims to synthesize the data on the effectiveness of pharmacological modulation of stress response in minimally invasive surgery. Eligible trials were clinical trials randomized or not or experimental trials that investigated the effect of pharmacological agents on modulation of surgical stress response to minimally invasive surgery. No clinical trials were identified. Eight experimental trials met the inclusion criteria and were obtained in full text. Experimental models were rats or rabbits subjected to pneumoperitoneum, or pneumoretroperitoneum, not to a whole operation. Pharmacological modulation of surgical stress response was attempted with erythromycin, melatonin, mesna, verapamil, pentoxifylline, N-acetylcysteine, and zinc. All the pharmacological agents, except pentoxifylline, seemed to reduce oxidative stress markers. However, only mesna pretreatment prevented oxidative stress, because oxidative stress markers remained in the sham levels. Contrasting data were obtained for pentoxyphilline. In conclusion, available data suggest that pharmacological modulation of surgical stress response to minimally invasive surgery might be feasible.
S
tress response is a well-conserved phenomenon across species from prokaryotes to human beings, characterized by induction of adaptive or protective mechanisms. Stress signal detection leads to the activation of stress signal pathways, with subsequent induction of gene transcription, protein translation, and alteration in the cell energy state. Surgical trauma is an ideal model for the investigation of stress response. During and after surgical procedures, there is a complex physiological stress response that involves the activation of inflammatory, endocrine, metabolic, and immunologic mediators. 1 Oxidative stress is an integral part of this surgical stress response.
Surgical stress response affects morbidity and mortality after surgical interventions, and modulation of surgical stress response is expected to improve the short-term and the long-term outcomes of major surgical interventions.
This modulation can be attempted both mechanically and pharmacologically.
Pharmacological modulation of oxidative stress response and of heat shock response has been successfully attempted in unicellular eukaryotic organisms, plants, and experimental animals. [2] [3] [4] [5] [6] [7] Moreover, pharmacological modulation of oxidative stress response by administration of drugs with antioxidant actions or supplementation of naturally occurring antioxidants in pharmacological concentrations has been shown to decrease morbidity and mortality in various patient populations. [8] [9] [10] Drugs have been administered either hours before exposure to stressful insults (preconditioning) or during the influence of the stressful insult, or after exposure to the stressful insult (postconditioning).
Although minimally invasive surgery [laparoscopic surgery, robotic surgery, Natural Orifice Transluminal Endoscopic Surgery (NOTES)] causes less trauma, it seems that reduction of surgical trauma does not eliminate surgical stress response. Minimally invasive surgery combined with modulation of surgical stress response could introduce a new era in therapeutics with clinical implications for the critically ill, for the hopefully increasing number of octagenarians, and for the patients who suffer from cancer.
This systematic review aims to synthesize the data on the effectiveness of pharmacological modulation of stress response in minimally invasive surgery.
MATERIALS AND METHODS

Search
Pubmed, Scopus, Science Citation Index, and Google Scholar were searched using the search terms "oxidative stress," "laparoscopic surgery," "pneumoperitoneum," "pneumoretroperitoneum," "minimally invasive surgery," "NOTES," "robotic surgery," "intra-abdominal pressure," "surgical stress," "surgical stress response," "preconditioning," "postconditioning," "modulation," "antioxidants," "antioxidant status," "MDA," and "glutathione" up to and including January 2010. There was no language restriction. The reference list of all the identified trials was checked for more relevant articles. For duplicate publications, the most complete report was selected.
Inclusion and Exclusion Criteria
Eligible trials were clinical trials randomized or not or experimental trials that investigated the effect of pharmacological agents on modulation of surgical stress response to minimally invasive surgery. Pharmacological interventions included pharmacological pretreatment (preconditioning), pharmacological postoperative treatment (postconditioning), and intraoperative administration of drugs that are anticipated to modulate surgical stress response. Eligible clinical trials should have at least 2 arms: 1 arm with subjects subjected to minimally invasive surgery and 1 arm with subjects exposed to a pharmacological agent before, during, or after minimally invasive surgical intervention. Eligible laboratory trials should have at least 3 arms: 1 arm with subjects subjected to a sham operation, 1 arm with laboratory animals subjected to minimally invasive surgery or pneumoperitoneum or pneumoretroperitoneum, and 1 arm with subjects exposed to a pharmacological agent before, during, or after minimally invasive surgical intervention. Eligible trials should provide measurements of oxidative stress markers and/or antioxidant defenses.
Trials that provided data on outcome measures probably related to oxidative stress, for example, renal perfusion without measuring oxidative stress markers was excluded. Trials that investigated the effect of anesthetics with possible prooxidant antioxidant properties were also excluded.
Data Analysis
Data extracted from eligible trials included the type of study, study design, type of operation, duration of operation, anesthetic agents, number of patients or experimental animals in each group, pharmacological agent tested for modulation of stress response, dose, route of administration, time point of exposure to the drug in relation to the surgical intervention, measured markers of surgical stress response, tissue used for measurement, method of measurement, time periods of measurement in relation to the operation, and statistical methods used for analysis of the results. Articles published only as abstracts, editorials, news, and correspondence sections were excluded.
A meta-analysis was not possible and the quality of the study was not assessed due to heterogeneity of study design or outcome measures.
RESULTS
Sixty-four trials were identified and their abstracts were reviewed. No clinical trials were identified, apart from those that investigated the effect of anesthetics on oxidative stress response to minimally invasive surgery, and were excluded according to the study protocol. [11] [12] [13] [14] [15] [16] However, while the manuscript was in the review process, a randomized clinical trial (RCT) was published that investigated the effect of melatonin on oxidative stress after laparoscopic cholecystectomy. 17 Three trials investigated pharmacological modulation of oxidative stress response in the context of laparoscopic surgery, but did not include oxidative stress measurements and therefore were also excluded. [18] [19] [20] The RCT included 41 patients; 20 received melatonin and 21 received placebo. Blood samples for measurement of malondialdeyde, ascorbic acid, total ascorbic acid, dehydroascorbic acid, and C-reactive protein were collected preoperatively and at 5 minutes, 6, and 24 hours after operation. No difference was found between groups on postoperative oxidative stress markers.
Eight experimental trials met the inclusion criteria and were obtained in full text. [21] [22] [23] [24] [25] [26] [27] [28] Experimental models were rats or rabbits subjected to pneumoperitoneum, or pneumoretroperitoneum, not to a whole operation. Pharmacological modulation of surgical stress response was attempted with erythromycin, melatonin, mesna, verapamil, pentoxifylline, N-acetylcysteine, and zinc (Tables 1 and 2) .
Heterogeneity was detected on the type of laboratory animal, on the type and number of measured oxidative stress markers, on tissue specimens utilized for measurement of oxidative stress, on the time points of measurement in relation to the operation, and on the laboratory methods used for the measurements. Five of the trials provided measurements of both oxidative stress markers and antioxidant status. 21, 22, 25, 27, 28 Lipid peroxides were the only marker of oxidative stress measured in all the trials, except the trial of Demirbas et al, 21 which additionally provided measurements of protein carbonyl content.
All the trials demonstrated that pneumoperitoneum causes oxidative stress, although discordant results were reported within some trials, with oxidative stress measurements implying oxidative stress response and antioxidant status measurements, indicating no effect of pneumoperitoneum on oxidative stress.
All the pharmacological agents, except pentoxifylline, seemed to reduce oxidative stress markers. However, only mesna pretreatment prevented oxidative stress, because oxidative stress markers remained in the sham levels. 25 Contrasting data were obtained for pentoxifylline. In the study by Nesek-Adam et al, 28 pentoxifylline did not affect oxidative stress, whereas in the trials by Dinckan et al 26 and Oksuz et al, 27 pentoxifylline reduced oxidative stress markers.
DISCUSSION
Modulation of stress response to minimally invasive surgery has been attempted in experimental trials. This modulation could be mechanical or pharmacological. Mechanical modulation of stress response to pneumoperitoneum has shown promising results, [29] [30] [31] [32] [33] [34] [35] but it is time consuming and perhaps it is difficult to apply in humans with comorbidities. Pharmacological modulation may be more feasible and could allow treatment individualization through choice of the appropriate drug regimen.
This systematic review shows that drugs with antioxidant properties could modulate the surgical stress response of experimental animals to pneumoperitoneum or pneumoretroperitoneum. However, there is not enough evidence to permit extraction of valid conclusions. First of all, the 8 experimental trials included in the review investigate 7 different pharmacological agents. Second, only 1 dose of each pharmacological agent was studied, thus hindering thorough investigation of the effect of the drug, because it is known that antioxidant agents may behave as prooxidants at different concentrations. These redox balance-modulating agents may have a favorable effect on the modulation of stress response either as prooxidants by induction of adaptive mechanisms of the organism or as antioxidants by scavenging of free radicals or promotion of antioxidant defenses.
Only for verapamil and pentoxifylline data were contributed by 2 and 3 different trials, respectively. For verapamil, the protocol was almost identical in both trials. However, the effect of pneumoperitoneum on antioxidant status was qualitatively different from the trial of Demirbas et al, 21 showing no effect of pneumoperitoneum on reduced glutathione concentration, and the trial of Guler et al, 22 demonstrating a reduction of glutathione concentration. In both trials, verapamil improved oxidative stress markers. Moreover, verapamil increased glutathione reductase levels in the trial of Demirbas et al, 21 whereas the drug had no effect on reduced glutathione concentration in the trial of Guler et al. The results were conflicting for pretreatment with pentoxifylline. One study showed no effect of pentoxifylline on oxidative stress markers, whereas the other study implied a protective effect of pentoxifylline on oxidative stress response 1 hour after deflation of pneumoperitoneum but failed to demonstrate any effect of pentoxifylline 1 hour after inflation. These conflicting results could be attributed to differences in the study design. The 2 studies of pentoxifylline were carried out in different experimental models, the route of administration of verapamil was intravenous in 1 study and intraperitoneal in the other study, and the time period of exposure to the drug before the surgical intervention was 2 hours in 1 study and almost null in the other study. Moreover, the trial that failed to show any effect of pentoxifylline provided data both on markers of oxidative stress and of antioxidant defenses, whereas the other study measured only markers of oxidative stress. The impact of these study design differences is not really known. However, literature data on the effect of pentoxifylline in liver ischemia reperfusion injury showed contradictory results depending on the route of administration. 36, 37 Yet, previous experimental data suggest that antioxidants are more effective, when administered just before exposure to stress, whereas prooxidants perform better when administered about 2 hours before stress. In accordance with this, exposure of experimental animals to pentoxifylline 5 minutes before desufflation led to attenuation of oxidative stress response.
A number of methodological issues were identified in the design of the experimental trials that affected the extraction of results. First of all, in the majority of the trials, experimental animals were not subjected to a whole operation. Thus, the question of the effect of pharmacological modulation of stress response to minimally invasive surgery cannot be answered on the basis of the available evidence. In addition, the effect of the drug alone on the oxidative status of the experimental animal was investigated only in the study by Ypsilantis et al. 25 Moreover, all the trials focused on oxidative stress without investigating the effect of pharmacological modulation on other aspects of surgical stress. Recently, an experimental trial showed a protective effect of the anti-inflammatory agent erdosteine on pneumoperitoneum-mediated lung injury. However, the results are based on histopathological analyses and no measurement of oxidative stress markers has been performed. 38 In fact, because surgical stress response encompasses different aspects of stress response-neurohormonal stress response, inflammatory, immune, metabolic, and oxidative stress response, modulation of surgical stress response is rather expected to be achieved by a multitarget drug approach than by a single target drug with a well-designed high affinity interaction with one of the cellular targets. Yet, multitarget drugs like salicylates and other nonsteroidal anti-inflammatory agents, acetaminophen, glutathion, and N-acetylcysteine have been shown to modulate oxidative stress response in unicellular eukaryotic microorganisms. However, their mechanism of action in modulation of stress response is not known and their effect on modulation of surgical stress response of experimental animals has not been investigated.
Only 1 RCT of pharmacological modulation of stress response to minimally invasive surgery was identified. The trial showed no effect of melatonin on oxidative stress markers in patients subjected to laparoscopic cholecystectomy. However, the number of patients was limited, the dosage regimen of melatonin might not be appropriate, and the effect of pharmacological modulation might be better detected in a major operation that elicits marked oxidative stress response. On the contrary, mechanical modulation was attempted in 1 clinical trial of laparoscopic cholecystectomy with favorable results. Moreover, there were clinical trials that had investigated the probable antioxidant effect of different anesthetics in minimally invasive surgery, but they were excluded as the aim of the study was not the comparison of anesthetic agents. A limitation of this systematic review is publication bias, arising from the greater publication probability of trials with positive results.
In conclusion, available data suggest that pharmacological modulation of surgical stress response to minimally invasive surgery might be feasible. However, further research is needed especially with multitarget drugs or drug combinations before concrete results can be obtained. Hence, the methodology of relevant trials should be standardized, so that valid results can be extracted before proceeding to the design of clinical trials. In addition, the desirable outcome of pharmacological preconditioning should be clearly determined as either reduction of oxidative stress markers or achievement of control levels of oxidative stress markers. 
